386 related articles for article (PubMed ID: 2497974)
1. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
3. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
4. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
5. Two antisense promoters in the immunoglobulin mu-switch region drive expression of c-myc in the Burkitt's lymphoma cell line BL67.
Apel TW; Mautner J; Polack A; Bornkamm GW; Eick D
Oncogene; 1992 Jul; 7(7):1267-71. PubMed ID: 1620543
[TBL] [Abstract][Full Text] [Related]
6. Oncogene expression and immunoglobulin synthesis in a North American Burkitt (NAB-2) lymphoma cell line with a 8;22 chromosome translocation.
Popescu NC; Dahlberg JE; Ablashi DV; Monastier M; Bona CA; DiPaolo JA; Hooper WC; Swan DC
Oncogene Res; 1990; 5(4):295-303. PubMed ID: 1697668
[TBL] [Abstract][Full Text] [Related]
7. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Ig gene expression by Ig binding factors. Suppression of alpha-H chain and lambda-2-L chain mRNA accumulation in MOPC-315 by IgA-binding factor.
Roman S; Moore JS; Darby C; Müller S; Hoover RG
J Immunol; 1988 May; 140(10):3622-30. PubMed ID: 3129498
[TBL] [Abstract][Full Text] [Related]
9. The block of elongation in c-myc exon 1 is abolished in Burkitt's lymphoma cell lines with variant translocation.
Eick D; Polack A; Kofler E; Bornkamm GW
Oncogene; 1988 Oct; 3(4):397-403. PubMed ID: 3078949
[TBL] [Abstract][Full Text] [Related]
10. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
11. Regulation of c-fgr proto-oncogene expression in Burkitt's lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels.
Sharp NA; Luscombe MJ; Clemens MJ
Oncogene; 1989 Aug; 4(8):1043-6. PubMed ID: 2548145
[TBL] [Abstract][Full Text] [Related]
12. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes.
Gregory CD; Kirchgens C; Edwards CF; Young LS; Rowe M; Forster A; Rabbitts TH; Rickinson AB
Eur J Immunol; 1987 Aug; 17(8):1199-207. PubMed ID: 3040424
[TBL] [Abstract][Full Text] [Related]
15. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
16. A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma.
Jain R; Roncella S; Hashimoto S; Carbone A; Francia di Celle P; Foa R; Ferrarini M; Chiorazzi N
J Immunol; 1994 Jul; 153(1):45-52. PubMed ID: 8207254
[TBL] [Abstract][Full Text] [Related]
17. Rearrangement of the c-myc oncogene with heavy-chain immunoglobulin enhancer in tumor DNA from an acute lymphoblastic leukemia patient.
Guerrasio A; Avanzi GC; Pegoraro L; Estivill X; Serra A; Giubellino MC; Fierro MT; Novarino A; Foa R; Saglio G
J Natl Cancer Inst; 1987 May; 78(5):845-51. PubMed ID: 3106693
[TBL] [Abstract][Full Text] [Related]
18. IL-4 (B cell stimulatory factor 1) overcomes Fc gamma receptor-mediated inhibition of mouse B lymphocyte proliferation without affecting inhibition of c-myc mRNA induction.
Phillips NE; Gravel KA; Tumas K; Parker DC
J Immunol; 1988 Dec; 141(12):4243-9. PubMed ID: 2974056
[TBL] [Abstract][Full Text] [Related]
19. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
Klein G
AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]